Panel Discussion | Mechanical Circulatory Support for High-Risk PCI and Shock

Tuesday, March 10, 2026

8:20 AM - 8:50 AM EST

Location: International Ballroom East

Moderator(s)

Mitchell Krucoff, MD, FACC, FAHA, FSCAI

Professor Medicine/Cardiology
Duke University Medical Center/Duke Clinical Research Institute
Durham, North Carolina, United States

Disclosure information not submitted.
Robert W. Yeh, MD, MSc

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure information not submitted.

Panel Discussant(s)

Suzanne J. Baron, MD, MSc

Interventional Cardiologist
Massachusetts General Hospital
Winchester, Massachusetts, United States

Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed Inc: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Acarix: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corp: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chiesi: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); PiCardia: Consulting Fees (e.g., advisory boards) (Ongoing); Recor Medical, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Michael C. John, MPH

United States

Disclosure information not submitted.
Jeffrey J. Popma, MD

Chief Scientific Officer
CRF
Newton, Massachusetts, United States

Disclosure(s): Medtronic: CMO ended Nov 2024 (Terminated, November 1, 2024), Stock-publicly held company (excluding mutual/index funds) (Terminated, November 1, 2024)
Charles A. Simonton, MD, FACC, FSCAI

EVP Chief Medical Officer
Abiomed a Johnson + Johnson MedTech Company
Charlotte, North Carolina, United States

Disclosure information not submitted.

Disclosure(s):

Suzanne J. Baron, MD, MSc: Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed Inc: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Acarix: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Boston Scientific Corp: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chiesi: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); PiCardia: Consulting Fees (e.g., advisory boards) (Ongoing); Recor Medical, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave Medical: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Zoll Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

David A. Morrow, MD: 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Jeffrey J. Popma, MD: Medtronic: CMO ended Nov 2024 (Terminated, November 1, 2024), Stock-publicly held company (excluding mutual/index funds) (Terminated, November 1, 2024)